TuisABCL • NASDAQ
add
AbCellera Biologics Inc
Vorige sluiting
$2,72
Dagwisseling
$2,62 - $2,75
Jaarwisseling
$2,34 - $6,05
Markkapitalisasie
795,60 m USD
Gemiddelde volume
1,87 m
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 6,51 m | -1,39% |
Bedryfskoste | 100,17 m | 324,95% |
Netto inkomste | -51,11 m | -78,63% |
Netto winsgrens | -785,42 | -81,16% |
Wins per aandeel | -0,17 | -70,00% |
EBITDA | -56,74 m | -15,44% |
Effektiewe belastingkoers | 18,40% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 643,14 m | -18,16% |
Totale bates | 1,39 mjd | -7,89% |
Totale aanspreeklikheid | 314,73 m | -4,46% |
Totale ekwiteit | 1,08 mjd | — |
Uitstaande aandele | 295,16 m | — |
Prys om te bespreek | 0,75 | — |
Opbrengs op bates | -16,69% | — |
Opbrengs op kapitaal | -20,12% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | -51,11 m | -78,63% |
Kontant van bedrywe | -28,88 m | -27 147,17% |
Kontant van beleggings | 3,70 m | 128,92% |
Kontant van finansiering | 3,14 m | -52,56% |
Netto kontantverandering | -21,67 m | -195,86% |
Beskikbare kontantvloei | -22,52 m | 42,04% |
Meer oor
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology firm that researches and develops human antibodies. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia. Wikipedia
HUB
Gestig
2012
Hoofkwartier
Webwerf
Werknemers
586
